7th Annual ALS ONE Research Symposium

November 22, 2024

ALS ONE's 7th Annual ALS ONE Research Symposium, held November 13, 14, and 15, 2024, hosted by our research team: Dr’s Merit Cudkowicz, MD, MSc of MGH, Robert H Brown, Jr. MD, DPhil of UMass Medical School, James Berry, MD, MPH of MGH, Sabrina Paganoni, MD, PhD of MGH, and Fernando Vieira, MD of ALS TDI, and in collaboration with Indu Navar and EverythingALS for Day 3's Neurotechnology Day.

The conference had over 900 registered guests from 37 countries, including researchers, scientists, and members of the ALS community from around the world, convening virtually for 3 days (Day 1: Keynote Speakers, Day 2: ALS Industry Day, Day 3: Neurotechnology Day), of sharing critical research that is underway across the globe to help uncover therapeutic options leading to an ultimate cure for Amyotrophic Lateral Sclerosis (ALS). Recordings were made of the presentations which we are/were approved to share.

« Previous

About Mitochon Pharmaceuticals

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival—similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth. Mitochon is supported by Ben Franklin Technology Partners Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority.